Radiographic lung density changes are observed in most patients after stereotactic body radiotherapy (SBRT) for lung cancer. In this study, we assessed the relationship between SBRT dose and our treatment technique. Follow-up CT density changes were used as a surrogate for lung injury from SBRT.
With the increasing patient population in the oncology world and advancing technologies in radiation oncology in particular, there is an increasing need for assistance in providing high-quality care.
NRG Oncology is a member of the National Cancer Institute (NCI) National Clinical Trials Network program and was created by the integration of three adult cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The Publications Working Group, has begun the amalgamation of three publications databases into one to track progress in manuscript development and to provide access to a comprehensive bibliography that incorporates the past/current research of all three legacy groups.
(P135) Dose Escalation Using Conventional Versus IMRT Planning for Hypofractionated Palliative Radiation of Lumbosacral Bony Metastases
The standard approach for palliation of bone metastasis (BM) is conventionally planned radiation (CRT). Randomized studies have shown the equivalence of hypofractionated vs conventionally fractionated regimens; yet, reported pain control is poor with either approach, resulting in some degree of pain relief in only 50% to 80% of cases and complete response in 15% to 60% of cases.
Our objective was to analyze the incidence of second primary cancer limited to the head and neck in a population with primary squamous cell carcinoma of the head and neck and its temporal trends in the human papillomavirus (HPV) era.
(P091) The Clinical Significance of Overlap or Underlap of the Prescription Isodose Line and Prostate Contour in Brachytherapy for Low-Risk Prostate Adenocarcinoma
While biochemical progression-free survival (BPFS) for prostate cancer treated with brachytherapy is excellent, reported outcomes differ between groups. One hypothesis that has been proposed for improved biochemical outcomes is prescribing to a planning target volume (PTV) that extends substantially beyond the prostate. We tested this hypothesis by analyzing the effect of overlap vs underlap between prescription isodose lines and prostate contours on BPFS. We also assessed whether these spatial differences are correlated with increased acute toxicity.
(S025) Radiation-Induced Increases in PARP1 Activity Predict for Long-Term Radiosensitization by PARP1 Inhibition in Preclinical Breast Cancer Models
The goal of this study was to optimize combination therapy with PARP1 inhibition and radiation for clinical assessment by establishing the most effective drug/radiation treatment schedule, determining the degree of PARP1-mediated radiosensitization across a range of drug doses, and identifying early biomarkers predictive of long-term treatment efficacy in preclinical BCa models.
(P134) Can a Radiation Oncology Social Media Website Be Used to Convey Reliable Radiation Oncology Information?
As the volume of radiation oncology information increases, the ability to gather and critically appraise high-quality information in order to answer clinical questions becomes increasingly challenging for radiation oncologists. Sharing knowledge about new information and practice variations is instrumental to high-quality radiation oncology practices.
(P090) Comparison of Intraoperatively Built Custom-Linked (IBCL) Seeds to Free Seeds for Permanent Prostate Brachytherapy
Our prostate brachytherapy technique at the Medical University of South Carolina evolved from implanting free seeds using a Mick Applicator (MA) (Mick Radio-Nuclear Instruments, Inc) to using intraoperatively built custom-linked (IBCL) seeds constructed with the QuickLink device (C.R. Bard, Inc). In this work, we compare dosimetric and early clinical outcomes using free seeds and IBCL seeds.
An unmet clinical need in breast cancer (BC) management is the identification of which patients will respond to radiation therapy (RT). We hypothesized that the integration of post-RT clonogenic survival data with gene expression data across a large spectrum of BC cell lines would generate a BC-specific RT sensitivity signature predictive for RT response in BC patients and allow identification of patients with tumors refractive to conventional therapy.